A Single-center,Double-blind,Randomised,Placebo-controlled,Parallel-group Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin on Insulin Sensitivity and Its Underlying Mechanism in Patients With T2DM Treated With Metformin.
Phase of Trial: Phase IV
Latest Information Update: 10 Sep 2015
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Apr 2013 Planned end date changed from 1 May 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
- 09 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.